Table of Contents
SWOT Analysis — 6
Australia Pharmaceuticals And Healthcare
Industry SWOT — 6
Australia Political
SWOT — 7
Australia Economic SWOT — 7
Australia Business Environment SWOT — 8
Pharmaceutical
Business Environment Ratings — 9
Table: Asia
Pharmaceuticals Business Environment Ratings — 9
Limits of
Potential Returns — 10
Risks to Realisation of
Returns — 10
Australia - Market
Summary — 12
Regulatory Regime — 14
Table: Priorities Of the Therapeutic Goods Administrations Strategic Plan,
2006-2008 — 14
OTC Switching
Climate — 15
Regional Regulatory
Harmonisation — 16
Recent Regulatory
Developments — 17
Intellectual Property
Issues — 18
Trade Agreements — 19
Pricing and Reimbursement — 20
Table: Historical PBS
Co-payments — 21
Price Cuts — 22
Additions to Reimbursed Drugs List — 24
Recent Pricing and
Reimbursement Developments — 25
Table New PBS
Formularies — 25
Industry Trends and
Developments — 27
Epidemiology — 27
Mental Health Issues — 29
Healthcare
Reforms — 31
E-Health — 33
Healthcare
Expenditure — 33
Prescribing
Patterns — 34
Private Healthcare
Insurance — 36
Domestic Pharmaceutical
Sector — 36
Foreign Industry — 37
Retail Pharmacy Sector — 38
Biotechnology and
Research — 40
Clinical Trials — 43
Medical Devices — 43
Table Examples Of Medical Devices
Classifications — 44
Recent Developments in the Medical
Devices Sector — 45
Industry Forecast
Scenario — 46
Overall Market
Forecast — 46
Table: Australia - Drug Expenditure
Indicators, Historical Data and Forecasts, 2003-2013 — 47
Key Growth Factors – Industry — 48
Table: Australia
- Health Expenditure Indicators, Historical Data and Forecasts,
2003-2013 — 49
Key Growth Factors –
Macroeconomic — 50
Table: Australia – Economic
Activity, 2006-2013 — 52
Prescription Market
Forecast — 53
Table: Australia - Prescription Market
Indicators, Historical Data and Forecasts (AUDmn unless otherwise
stated) — 54
Patented Drug Market
Forecast — 55
Table: Australia - Patented Market Data And
Forecasts, Historical Data and Forecasts, 2003-2013 — 55
Generics Market Forecasts — 56
Table: Australia - Generics
Market Indicators, Historical Data and Forecasts,
2003-2013 — 57
OTC Market
Forecast — 58
Table: Australia - OTC Market Indicators,
Historical Data and Forecasts (AUDmn unless otherwise
stated) — 59
Pharmaceutical Trade
Forecasts — 60
Table: Australia – Pharmaceutical
Trade Indicators, Historical Data and Forecasts, 2003-2013
(US$mn) — 61
Other Healthcare Data
Forecasts — 61
Table: Australia - Other Healthcare Data
And Forecasts, Historical Data and Forecasts,
2003-2013 — 62
Key Risks to BMI’s Forecast
Scenario — 62
Competitive
Landscape — 63
Pharmacy Over-The-Counter Medicine Sales In
Australia (US$) 2007 — 64
Company
Profiles — 65
Leading
Multinationals — 65
Pfizer — 65
Sanofi-Aventis — 67
GlaxoSmithKline — 69
Merck Sharp & Dohme
(Australia) — 72
Novartis — 75
Roche — 77
AstraZeneca — 79
Eli
Lilly — 81
Indigenous
Manufacturers — 84
Sigma
Pharmaceuticals — 84
Australian Pharmaceutical
Industries — 87
Alphapharm (incorporated into
Mylan) — 89
Herron
Pharmaceuticals — 91
Mayne Pharma
(Hospira) — 93
BMI Forecast
Modelling — 95
How We Generate Our Pharmaceutical Industry
Forecasts — 95
Pharmaceutical Business Environment Ratings
Methodology — 96
Ratings Overview — 96
Table: Pharmaceutical Business Environment Indicators — 97
Weighting — 98
Table: Weighting Of
Components — 98
Sources — 98
| 
View Cart
